Vitrolife AB (publ) - Fourth quarter and full year report 2025

Vitrolife AB (publ) reported its fourth-quarter and full-year results for 2025, revealing significant challenges and a notable impairment charge. In Q4, sales amounted to SEK 891 million, reflecting a 7% decrease compared to the same quarter the previous year, influenced significantly by a -10% currency impact. Organic growth in local currencies, excluding discontinued businesses, was 6%. A breakdown by region showed varied performance: a slight decline in EMEA, a 9% growth in the Americas, and a robust 10% increase in APAC. Product categories saw increases of 10% in Consumables and 6% in Technologies.

However, the company faced a decreased gross margin, dropping to 58.0% from 61.1%, primarily due to restructuring costs of SEK 55 million. EBITDA fell to SEK 196 million, down from SEK 337 million, and the corresponding EBITDA margin decreased to 22.0%. Most concerning was an impairment charge of SEK 5,357 million, leading to a stark net income of SEK -5,314 million and an earnings per share of SEK -39.24.

For the full year, total sales were SEK 3,440 million, a decline from SEK 3,609 million, again largely due to currency effects (-6%). Despite some regional and product group growth, the overall gross margin was slightly reduced to 58.1%. EBITDA for the year was SEK 949 million, with an EBITDA margin of 27.6%. The impairment charge weighed heavily on net income, which fell to SEK -5,013 million, producing an earnings per share of SEK -37.01.

Finally, despite these challenges, the Board proposed maintaining the dividend at SEK 1.10 per share, reflecting resilience amid notable financial difficulties.

**Market Analysis of Vitrolife AB (publ) – Q4 and Full Year 2025**

Vitrolife AB (publ) presented a challenging fourth quarter and full-year report for 2025, signaling areas of concern yet also potential resilience. Sales for the fourth quarter declined to SEK 891 million, reflecting a 7% drop year-over-year due primarily to adverse currency fluctuations impacting the reported figures. Notably, the company's organic growth in local currencies showcased a more promising 6%, underlining the resilience of the underlying business despite external pressures.

Regionally, the Americas showed the most robust growth at 9%, followed by Asia-Pacific with 10%. The EMEA region, on the other hand, demonstrated a contraction of 1%, indicating varying demand dynamics that warrant closer observation. The product group performance was more mixed, with consumables (+10%) outperforming technologies (+6%) and genetics (+1%).

The significant decline in gross margin from 61.1% to 58.0% suggests rising costs, potentially driven by raw materials or operational inefficiencies. EBITDA decreased sharply, reflecting a contraction in profitability margins amid restructuring efforts and an impairment charge totaling SEK 5,357 million. When excluding these one-off costs, the adjusted EBITDA and net income were modest, yet they highlighted Nicolai Havon’s strategic initiatives, which may prove beneficial in the long run.

While the proposed dividend remains consistent at SEK 1.10, investor sentiment may be influenced by the net income loss of SEK 5,314 million, along with the impairment charge. The company’s future performance will heavily depend on its ability to navigate currency volatility and achieve operational efficiencies.

In conclusion, while Vitrolife faces significant short-term challenges, the underlying growth trends in local markets and product lines posit a potential recovery trajectory. Investors should exercise caution but consider the stock as a potential opportunity, particularly if broader market conditions stabilize. Analysts should keep a close eye on subsequent quarters to assess the effectiveness of ongoing restructuring and growth strategies.